< View ETF products

Invesco NASDAQ Biotech UCITS ETF Acc

Investment Risks

For complete information on risks, refer to the legal documents. The value of investments, and any income from them, will fluctuate. This may partly be the result of changes in exchange rates. Investors may not get back the full amount invested. The Fund’s ability to track the benchmark’s performance is reliant on the counterparties to continuously deliver the performance of the benchmark in line with the swap agreements and would also be affected by any spread between the pricing of the swaps and the pricing of the benchmark. The insolvency of any institutions providing services such as safekeeping of assets or acting as counterparty to derivatives or other instruments, may expose the Fund to financial loss. The Fund might be concentrated in a specific region or sector or be exposed to a limited number of positions, which might result in greater fluctuations in the value of the Fund than for a fund that is more diversified. The value of equities and equity-related securities can be affected by a number of factors including the activities and results of the issuer and general and regional economic and market conditions. This may result in fluctuations in the value of the Fund. The fund might purchase securities that are not contained in the reference index and will enter into swap agreements to exchange the performance of those securities for the performance of the reference index.

Product description

The Invesco NASDAQ Biotech UCITS ETF Acc aims to provide the total return performance of the NASDAQ Biotechnology Index (the “Reference Index”), less the impact of fees.

The Reference Index comprises biotechnology and pharmaceuticals companies (as defined by ICB) listed on the NASDAQ Stock Market.  Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: the largest five constituents are capped at 8%; the remaining constituents are capped at 4%. The Reference Index is rebalanced quarterly and reviewed annually in December.

The fund aims to achieve its objective by holding a basket of equities, which typically delivers most of the fund’s return but ordinarily would not be the same as those in the Reference Index. The fund will also use unfunded swaps, which are contracts whereby one or more approved counterparties agrees to exchange with the fund any difference between the returns of the Reference Index and the basket of equities held. The aim is to achieve a closer and more consistent performance relative to the Reference Index than would generally be possible through physical replication alone.

This ETF is passively managed.

Trading information

London Stock Exchange
Trading currency USD
Settlement period T+2
Exchange ticker SBIO
Bloomberg ticker SBIO LN
Bloomberg iNAV SBIOIN
Reuters ticker SBIO.L
Reuters iNAV 0J1KINAV.DE
WKN A12CCJ
Valor 25524842
Sedol BQY79Y5

Data source: London Stock Exchange Group

SIX Swiss Exchange
Trading currency USD
Settlement period T+2
Exchange ticker SBIO
Bloomberg ticker SBIO SW
Bloomberg iNAV SBIOIN
Reuters ticker SBIO.S
Reuters iNAV 0J1KINAV.DE
WKN A12CCJ
Valor 25524842

Data source: London Stock Exchange Group

Euronext Milan
Trading currency EUR
Settlement period T+2
Exchange ticker SBIO
Bloomberg ticker SBIO IM
Bloomberg iNAV SBIOINE
Reuters ticker SBIO.MI
Reuters iNAV 0J1JINAV.DE
WKN A12CCJ
Valor 25524842

Data source: London Stock Exchange Group

Deutsche Börse (Xetra)
Trading currency EUR
Settlement period T+2
Exchange ticker NBTK
Bloomberg ticker NBTK GY
Bloomberg iNAV SBIOINE
Reuters ticker NBTK.DE
Reuters iNAV 0J1JINAV.DE
WKN A12CCJ
Valor 25524842

Data source: London Stock Exchange Group

Euronext Amsterdam
Trading currency EUR
Settlement period T+2
Exchange ticker SBIO
Bloomberg ticker SBIO NA
Bloomberg iNAV SBIOINE
Reuters ticker SBIO.AS
Reuters iNAV 0J1JINAV.DE
WKN A12CCJ
Valor 25524842

Data source: London Stock Exchange Group

Key information

Bloomberg ticker SBIO LN
ISIN IE00BQ70R696
Benchmark BBG ticker XNBI
Management fee 0.40%
Swap fee 0.00%
NAV (18 Apr 2024) $41.91
AUM $416,813,677
Base currency USD
Replication method Synthetic
Summary Risk Indicator (SRI) 5
Umbrella AUM (18 Apr 2024) $44,881,526,412

ESG Profile

(Index 18 Apr 2024)

ESG Rating (AAA-CCC) A
Quality Score (0-10) 6.20
Carbon Intensity 24.19

Source: MSCI ESG Research. For more information on the ESG profile, see the ESG section on this product page. Carbon intensity is the weighted average carbon intensity (Tons CO2e/$million sales).

Key documents

Invesco NASDAQ Biotech UCITS ETF Acc - Factsheet EN File icon
Invesco NASDAQ Biotech UCITS ETF Acc - Factsheet DE File icon
Invesco NASDAQ Biotech UCITS ETF Acc - Factsheet DE File icon
Invesco NASDAQ Biotech UCITS ETF Acc - Factsheet EN File icon
Invesco NASDAQ Biotech UCITS ETF Acc - Factsheet FR File icon

Costs may increase or decrease as result of currency and exchange rate fluctuations. Consult the legal documents for further information on costs.

The investment concerns the acquisition of units in a fund and not in a given underlying asset.

Nasdaq®, NASDAQ Stock Market® are registered trademarks of Nasdaq, Inc. (which with its affiliates is referred to as the “Corporations”) and are licensed for use by Invesco UK Services Limited. The Product(s) have not been passed on by the Corporations as to their legality or suitability. The Product(s) are not issued, endorsed, sold, or promoted by the Corporations. The Corporations make no warranties and bear no liability with respect to the product(s).

The performance information on this web page refers to past performance. Past performance is not a reliable indicator of future returns.

The data shown on this page is not real-time, i.e. it may be delayed due to mandatory requirements of the data provider. As a consequence, the price of the product linked to a specific underlying you are quoted by your broker or intermediary may substantially differ from the price of the product that you would expect on the basis of the data displayed on this site. Invesco accepts no responsibility for loss, however caused, resulting from errors in this data.

ETF performance is in the fund’s base currency, includes dividends, reinvested. ETF performance is Net Asset Value after management fees and other ETF costs but does not consider any commissions or custody fees payable when buying, holding or selling the ETF. The ETF does not charge entry or exit fees. Data: Invesco.

 

The risk / reward profile classifies the fund by an indicator representing the levels from the lowest (1) to the highest (7). For more information see the KID/KIID.

 

London Stock Exchange®, London Stock Exchange Group®, any short-form names, logos and titles (such as LSEG), are trade marks of London Stock Exchange plc and its affiliates. Where data on this website is attributed to the London Stock Exchange Group, that data is made available pursuant to a delayed redistribution data licence agreement, whereby the original source of such data is the London Stock Exchange Group.

Copyright © London Stock Exchange plc, 2024. All rights reserved.

Use, duplication, or sale of this service, or data contained herein, except for the licensable activities undertaken on this website as described in the delayed redistribution data licence agreement with London Stock Exchange plc, is strictly prohibited.